KBC Group NV Lowers Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

KBC Group NV reduced its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 93.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,131 shares of the medical instruments supplier's stock after selling 16,172 shares during the period. KBC Group NV's holdings in ICU Medical were worth $157,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. US Bancorp DE increased its stake in ICU Medical by 9.0% during the 4th quarter. US Bancorp DE now owns 3,832 shares of the medical instruments supplier's stock valued at $595,000 after purchasing an additional 315 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of ICU Medical by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 304,155 shares of the medical instruments supplier's stock valued at $47,196,000 after buying an additional 3,048 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of ICU Medical in the 4th quarter valued at $5,779,000. Arizona State Retirement System increased its position in shares of ICU Medical by 1.0% in the 4th quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier's stock valued at $1,044,000 after acquiring an additional 65 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in ICU Medical in the 4th quarter worth $10,003,000. Hedge funds and other institutional investors own 96.10% of the company's stock.

Analysts Set New Price Targets

ICUI has been the subject of several research analyst reports. Raymond James Financial reduced their price objective on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research note on Friday, May 9th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. KeyCorp dropped their price objective on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Finally, Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ICU Medical presently has an average rating of "Buy" and a consensus price target of $192.67.

ICU Medical Stock Performance

ICUI stock traded up $3.19 during trading on Wednesday, hitting $135.73. 204,465 shares of the company traded hands, compared to its average volume of 259,860. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.59 and a quick ratio of 1.52. ICU Medical, Inc. has a 1 year low of $117.92 and a 1 year high of $196.26. The stock's 50-day simple moving average is $133.89 and its 200 day simple moving average is $145.29. The company has a market cap of $3.34 billion, a PE ratio of -35.44 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to analysts' expectations of $574.15 million. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The business's revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.96 EPS. On average, equities analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Activity

In other ICU Medical news, Director David C. Greenberg sold 1,942 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $143.66, for a total value of $278,987.72. Following the sale, the director directly owned 6,760 shares of the company's stock, valued at approximately $971,141.60. This trade represents a 22.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ben Sousa sold 2,000 shares of ICU Medical stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the sale, the insider directly owned 479 shares in the company, valued at $65,795.44. This represents a 80.68% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,097 shares of company stock valued at $4,860,156. Insiders own 1.50% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.